ICCC
$6.05
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
Recent News
ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
ImmuCell Corp (ICCC) reports improved profitability and gross margins, while addressing sales declines and strategic shifts for future growth.
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve
ICCC's 2025 sales rise 4.3% y/y, with the gross margin expanding sharply, helping narrow its annual net loss despite asset write-downs and strategic shifts.
ImmuCell Q4 Earnings Call Highlights
ImmuCell (NASDAQ:ICCC) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight a year of operational change, improved margins, and a strategic pivot toward expanding its First Defense calf scours prevention franchise while stepping away from investment in its Re-Ta
ImmuCell Corporation Q4 2025 Earnings Call Summary
Moby summary of ImmuCell Corporation's Q4 2025 earnings call
Niche Focus & Regulation Shape the Future of Healthcare Firms
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.